Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Dana-Farber Brigham Cancer Center, University of California, Los Angeles, Yale University, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Colorado Cancer Center, University of Colorado Anschutz, The Ohio State University Wexner Medical Center, Washington University in St. Louis, Comprehensive Cancer Centers of Nevada
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4213030276